The results were bad but not fatal.

I think it's best it came out in Ph2 rather than in Ph3. A COVID drug can still be taken to market. The FDA has already called for an Advisory Committee FDA meeting for Merck, so don't expect a quick approval without scrutiny

We know it has a viral reduction impact. That was proven in the hospital setting. If the same trial was run as Merck did, the results could have been very similar.

We know it works best on high risk individuals.

We know Roche did not pull the plug.

We know 10$/ share is the cash value of the company

We also know they have antivirals for Dengue, Hep C and RSV in the pipeline.

Analyst price targets will still be in the $25-40 range once they update their ratings$Atea Pharmaceuticals, Inc.(AVIR)$

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论